MIAMI, Sept. 12, 2017 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ:OPK) (“OPKO” or “the Company”) announces that GeneDx will be showcasing its leadership in genetic and genomic testing with more than 35 poster and platform presentations at the National Society of Genetic Counselors (NSGC) and the American Society of Human Genetics (ASHG) annual meetings this fall. At the 36th Annual National Society of Genetic Counselors […]
MIAMI, June 07, 2017 (GLOBE NEWSWIRE) — OPKO Health, Inc. (Nasdaq:OPK) announced today that GeneDx, a business unit of OPKO’s BioReference Laboratories division, extended its relationship with the University of California Health (UC Health) for genetic, genomic, and molecular testing services. UC Health, one of the nation’s leaders in genomics and precision medicine in both the clinical and investigational arenas, has selected GeneDx to supplement […]
MIAMI, May 18, 2017 (GLOBE NEWSWIRE) — OPKO Health, Inc.(NASDAQ:OPK), announces that data from a prospective study conducted at Veteran Affairs (VA) hospitals confirming the 4Kscore test’s ability to accurately predict aggressive prostate cancer were presented in a podium presentation on May 16, 2017 at the 112thAmerican Urological Association (AUA) Annual Meeting in Boston. The study entitled, “An Independent, Multi-Institutional, Prospective […]
MIAMI, March 07, 2017 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ:OPK) announces that GenPath Women’s Health, a business unit of OPKO Health subsidiary BioReference Laboratories, will offer ClariTest™, a non-invasive prenatal test (NIPT) initially to be performed at Illumina, Inc. (NASDAQ:ILMN) on the Verifi™ platform. This platform utilizes massively parallel sequencing technology to screen for trisomies 13, 18, 21 and sex chromosome abnormalities, with […]
Launching New Genetic Tests in Multiple Indications Multiple Poster and Platform Presentations Highlight GeneDx’ Broad Offerings in a Variety of Genetic Specialties MIAMI, March 14, 2017 (GLOBE NEWSWIRE) — OPKO Health, Inc. (NASDAQ:OPK) announces that GeneDx, a subsidiary of OPKO Health, will have a prominent presence at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting taking place from March 21-24, […]
MIAMI, Feb. 28, 2017 (GLOBE NEWSWIRE) — OPKO Health, Inc.(NASDAQ:OPK), today announces that GeneDx, a subsidiary of OPKO Health, is proud to participate as a founding member in Illumina Inc.’s (NASDAQ:ILMN) iHope Network on International Rare Disease Day, which takes place today. iHope Network is led by a group of clinical laboratory partners committed to providing clinical whole-genome sequencing (cWGS) to […]
MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NASDAQ:OPK), announces the appointment of Benjamin D. Solomon, M.D. as Managing Director of GeneDx, effective as of October 3, 2016. GeneDx, part of OPKO’s BioReference Laboratories subsidiary, specializes in genetic testing for rare hereditary disorders. Dr. Solomon is a pediatric geneticist who focuses on the use of genetics and genomics to identify, understand and care for patients […]
MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (Nasdaq: OPK) announces the appointment of Jane Pine Wood, Esq. as Chief Legal and Compliance Officer of its wholly owned subsidiary, BioReference Laboratories, effective October 1, 2016. Ms. Wood is a nationally respected healthcare attorney who has been practicing law for 29 years. She specializes in laboratory regulatory and compliance matters, and has counseled more than 500 […]
MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE: OPK) today announced that senior management will discuss recent draft local coverage determinations by certain Medicare Administrative Contractors for OPKO’s 4Kscore® test at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2016 at 11:30 AM (EDT). OPKO previously announced that Novitas Solutions issued a positive draft local coverage determination proposing to establish reimbursement coverage for patients with PSA […]
MIAMI–(BUSINESS WIRE)– OPKO Health, Inc. (NYSE:OPK) (“OPKO” or the “Company”) announces that Novitas Solutions has issued a draft local coverage determination for the 4Kscore® Test, the only blood test that accurately identifies an individual patient’s risk for high-grade, aggressive prostate cancer. Novitas Solutions is a Medicare Administrative Contractor (MAC) for Medicarejurisdictions L and H, with responsibility for nearly 10 million Medicare beneficiaries in New Jersey, Pennsylvania, Maryland, the District […]